ArticleClinical journal of gastroenterology2011
Proton pump inhibitors: use, misuse and concerns about long-term therapy.
Article in Clinical journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Survey-Based Analysis of Current Trends for Prescribing Gastrointestinal Protectants among Small-Animal General Practitioners in Portugal.Veterinary sciences · 2021Article
- Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics.Gastroenterology research · 2019Article
- ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.Journal of veterinary internal medicine · 2018Article
- Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Clinical drug investigation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are widely used in acid-related disorders of the stomach and oesophagus. Treatment with PPIs is usually extended indefinitely for maintaining symptom control, putting the patient at risk of adverse effects. On the other hand, there is also a tendency for physicians to prescribe these drugs unnecessarily for minor dyspepsia. The use of these best-selling drugs is expected to increase further as they are now available over-the-counter in many countries . Several newer PPIs are now available on the market with claims of superior therapeutic efficacy which are also excessively prescribed without considering their cost-effectiveness. This article examines why PPIs are now the leading antisecretory drugs, clinical aspects to be considered when prescribing newer PPIs, indications and recommended duration of treatment in each situation, over-prescription of PPIs, and adverse reactions that can emerge with long-term use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.